Elutia share price logo

Elutia

NASDAQ: ELUT

$0.80

+0.02

(+2.92%)

Live

as on

Elutia Stock Performance

as on October 6, 2026 at 6:19 am IST

  • Day's Low

    Day's High

    $0.72
    $0.81
    downward going graph

    10.16%

    Downside

    1.07%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.50
    $1.39
    downward going graph

    37.61%

    Downside

    72.82%

    Upside

    downward going graph

Elutia share price movements today

Previous Close
$0.78
Open
$0.76
Volume
1.5M
Market Cap
$34.5M
Day's Low - High
$0.72 - $0.81
52 Week Low - High
$0.50 - $1.39

Elutia Historical Returns

1 Month Return
-5.18 %
3 Month Return
-16.45 %
1 Year Return
-11.51 %
3 Year Return
-39.64 %
5 Year Return
0 %

Elutia Stock Fundamentals & Key Indicators

Check Elutia market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$34.5M

EPS (TTM)

1.301

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0.6

Industry PE ratio

-2.33

PEG Ratio

0.00

EBITDA

-24.1M

Revenue (TTM)

12.1M

Profit Margin

57.82%

Return On Equity TTM

940.81%

Elutia vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Elutia with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Elutia image
Elutia
Buy$34.5MNA0.6057.82%0.00%
Edwards Lifesciences image
Edwards Lifesciences
Buy$49.0B-21.76%48.9477.98%0.00%
Medtronic image
Medtronic
Buy$110.5B-31.34%21.1266.69%3.31%
Stryker image
Stryker
StrongBuy$105.6B4.93%28.3165.17%1.28%
Abbott Laboratories image
Abbott Laboratories
StrongBuy$168.7B-15.86%31.3556.80%2.54%
See all

Stock Returns calculator for Elutia Stock including INR - Dollar returns

The Elutia stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Elutia investment value today

Current value as on today

₹98,840

Returns

-₹1,160

(-1.16%)

Returns from Elutia Stock

-₹8,932 (-8.93%)

Dollar Impact

₹7,772 (+7.77%)

Analyst Recommendation on Elutia Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Elutia. Average target price of $5

Elutia Share Price Target

Get share price movements and forecasts by analysts on Elutia.

What analysts predicted

83.97%UPSIDE

Target Price

$5

Current Price

$0.8014

Analyzed by

8 Analysts

Target

$5.00

Elutia target price $5, a slight upside of 83.97% compared to current price of $0.8014. According to 8 analysts rating.

Indian Investors' Interest in Elutia Stock

Search interest for Elutia Stock has increased by 156% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:156% versus previous 30 day period

Elutia Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
6
6
5
5
6
6
3
3
3
2
Gross Profit
2
2
2
2
2
3
1
1
1
1
Operating Income
-8
-8
-10
-8
-7
-9
-4
-5
-5
-7
EBITDA
-15
-26
3
-7
-1
-8
0
-9
-7
-7
Interest Expense
1
1
1
1
1
0
0
-3
0
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-17
-28
1
-9
-3
-9
0
-6
-7
-7
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-17
-28
1
-9
-3
-9
-3
70
-7
-7
Net Profit Margin
42.47%
44.49%
46.29%
42.50%
40.75%
48.83%
55.76%
58.51%
57.87%
59.62%

Elutia Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
39
42
42
47
23
24
24
12
Gross Profit
15
19
20
19
11
11
10
6
Operating Income
-8
-8
-13
-23
-35
-30
-35
-18
EBITDA
-2
-2
-12
-15
-27
-31
-45
-13
Interest Expense
5
5
5
5
5
5
4
0
Depreciation
3
3
3
3
3
3
3
2
Income Before Tax
-11
-11
-21
-24
-36
-41
-54
-15
Income Tax Expense
0
0
0
0
0
0
0
0
Net Income
-11
-11
-21
-24
-32
-37
-53
53
Net Profit Margin
40.84%
46.08%
48.17%
40.14%
48.80%
44.67%
43.93%
53.66%

Elutia Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-17
-28
1
-9
-3
-9
-
70
-7
-7
Operating Cash Flow
-2
-4
-3
-12
-8
-8
-2
-24
-7
-8
Investing Cash Flow
0
0
0
0
0
0
0
79
0
0
Financing Cash Flow
-4
9
11
0
13
0
0
-23
0
0
Change in Cash
-6
5
7
-12
4
-8
-3
31
-7
-8

Elutia Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-11
-11
-21
-24
-32
-37
-53
53
Operating Cash Flow
-5
-7
-13
-15
-21
-21
-22
-44
Investing Cash Flow
0
0
0
0
0
14
0
78
Financing Cash Flow
6
7
51
6
8
9
17
-10
Change in Cash
1
0
36
-9
-13
2
-6
23

Global Institutional Holdings in Elutia

Check out the Institutions with significant holdings in Elutia.

Funds
Holdings
Vanguard
2.63%
VANGUARD INDEX FUNDS
2.31%
Fidelity Concord Street Trust
0.48%
iShares
0.25%
World Funds Trust
0.08%
See all

Elutia News & Key Events

  • img

    Today's Timeline - 01 October

    Fri, 02:20 AM

    -

    Elutia receives full $8M escrow payment from BioEnvelope sale to Boston Scientific, funding NXT-41x launch through 2029.

Insights on Elutia

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Edwards Lifesciences Corp has given 10.5% return, outperforming this stock by 22.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Edwards Lifesciences Corp has given 17.9% return, outperforming this stock by 57.5%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 70.79M → -7.64M (in $), with an average decrease of 56.5% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, ELUT stock has moved down by -33.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 5 quarters, 6.26M → 2.42M (in $), with an average decrease of 18.8% per quarter

About Elutia

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
OrganisationElutia
Headquarters20 Firstfield Road, Gaithersburg, MD, 20878, US
IndustryBiotechnology
CEOC. Randal Mills

Key Management of Elutia

Name

Title

Mr. Peter J. Ligotti

Chief Commercial Officer

Mr. Jeffry D. Hamet

Senior VP of Finance, Treasurer & Secretary

Dr. C. Randal Mills Ph.D.

Co-Founder, President, CEO & Director

Mr. Matthew B. Ferguson

Chief Financial Officer

Dr. Michelle LeRoux Williams Ph.D.

Chief Scientific Officer

Ms. Tamara Grossett

Head of People

Dr. Sonali Fonseca Ph.D.

VP & Head of Emerging Businesses

Mr. Dwayne Montgomery

Head of Cardiovascular

FAQs

What is Elutia share price today?

Elutia share price today is $0.80 as on . Elutia share today touched a day high of $0.81 and a low of $0.72.

What is the 52 week high and 52 week low for Elutia share?

Elutia share touched a 52 week high of $1.39 on and a 52 week low of $0.50 on . Elutia stock price today i.e. is trending at $0.80,which is 42.14% down from its 52 week high and 60.28% up from its 52 week low.

What is Elutia's market capitalisation today?

Elutia market capitalisation is $0.00T as on .

How to invest in Elutia Stock (ELUT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Elutia on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Elutia Stock (ELUT) from India?

Indian investors can start investing in Elutia (ELUT) shares with as little as ₹96.292503356934 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹962.93 in Elutia stock (as per the Rupee-Dollar exchange rate as on ). Based on Elutia share’s latest price of $0.80 as on October 6, 2026 at 12:49 am IST, you will get 12.4782 shares of Elutia. Learn more about fractional shares .